Author:
Won Elizabeth,Janjigian Yelena J.,Ilson David H.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference43 articles.
1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 1996;335:462–7.
3. Bang YJ, Van Custem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2-positive advanced gastric or gastro-oesophageal cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97. This phase III study showed a survival and PFS benefit of trastuzumab in combination with chemotherapy for HER2 positive EG cancers and provides the rationale for FDA approval of the drug.
4. Yarden Y. The EGFR family and its ligands in human cancer, signaling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3–8.
5. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(Suppl):15. abst 4556.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献